SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Centers for Disease Control and Prevention. The burden of chronic diseases and their risk factors: national and state perspectives 2004. Atlanta: US Dept. of Health and Human Services; 2004. URL: www.cdc.gov/nccdphp/burdenbook2004.
  • 2
    Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD, Vignon E. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis 2001; 60: 61926.
  • 3
    Jordan KM, Syddall HE, Garnero P, Gineyts E, Dennison EM, Sayer AA, et al. Urinary CTX-II and glucosyl-galactosyl-pyridinoline are associated with the presence and severity of radiographic knee osteoarthritis in men. Ann Rheum Dis 2006; 65: 8717.
  • 4
    Reijman M, Hazes JM, Bierma-Zeinstra SM, Koes BW, Christgau S, Christiansen C, et al. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 2004; 50: 24718.
  • 5
    Elliott AL, Kraus VB, Luta G, Stabler T, Renner JB, Woodard J, et al. Serum hyaluronan levels and radiographic knee and hip osteoarthritis in African Americans and Caucasians in the Johnston County Osteoarthritis Project. Arthritis Rheum 2005; 52: 10511.
  • 6
    Clark AG, Jordan JM, Vilim V, Renner JB, Dragomir AD, Luta G, et al. Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project. Arthritis Rheum 1999; 42: 235664.
  • 7
    Vilim V, Vytasek R, Olejarova M, Machacek S, Gatterova J, Prochazka B, et al. Serum cartilage oligomeric matrix protein reflects the presence of clinically diagnosed synovitis in patients with knee osteoarthritis. Osteoarthritis Cartilage 2001; 9: 6128.
  • 8
    Otterness IG, Swindell AC, Zimmerer RO, Poole AR, Ionescu M, Weiner E. An analysis of 14 molecular markers for monitoring osteoarthritis: segregation of the markers into clusters and distinguishing osteoarthritis at baseline. Osteoarthritis Cartilage 2000; 8: 1805.
  • 9
    Dragomir AD, Kraus VB, Renner JB, Luta G, Clark A, Vilim V, et al. Serum cartilage oligomeric matrix protein and clinical signs and symptoms of potential pre-radiographic hip and knee pathology. Osteoarthritis Cartilage 2002; 10: 68791.
  • 10
    Kelman A, Lui L, Yao W, Krumme A, Nevitt M, Lane NE. Association of higher levels of serum cartilage oligomeric matrix protein and N-telopeptide crosslinks with the development of radiographic hip osteoarthritis in elderly women. Arthritis Rheum 2006; 54: 23643.
  • 11
    Ding C, Garnero P, Cicuttini F, Scott F, Cooley H, Jones G. Knee cartilage defects: association with early radiographic osteoarthritis, decreased cartilage volume, increased joint surface area and type II collagen breakdown. Osteoarthritis Cartilage 2005; 13: 198205.
  • 12
    Garnero P, Peterfy C, Zaim S, Schoenharting M. Bone marrow abnormalities on magnetic resonance imaging are associated with type II collagen degradation in knee osteoarthritis: a three-month longitudinal study. Arthritis Rheum 2005; 52: 28229.
  • 13
    King KB, Lindsey CT, Dunn TC, Ries MD, Steinbach LS, Majumdar S. A study of the relationship between molecular biomarkers of joint degeneration and the magnetic resonance-measured characteristics of cartilage in 16 symptomatic knees. Magnetic Res Imag 2004; 22: 111723.
  • 14
    O'Reilly SC, Muir KR, Doherty M. Screening for pain in knee osteoarthritis: which question? Ann Rheum Dis 1996; 55: 9313.
  • 15
    Jordan JM, Luta G, Stabler T, Renner JB, Dragomir AD, Vilim V, et al. Ethnic and sex differences in serum levels of cartilage oligomeric matrix protein: the Johnston County Osteoarthritis Project. Arthritis Rheum 2003; 48: 67581.
  • 16
    Disler DG, McCauley TR, Kelman CG, Fuchs MD, Ratner LM, Wirth CR, et al. Fat-suppressed three-dimensional spoiled gradient-echo MR imaging of hyaline cartilage defects in the knee: comparison with standard MR imaging and arthroscopy. Am J Roentgenol 1996; 167: 12732.
  • 17
    Recht MP, Kramer J, Marcelis S, Pathria MN, Trudell D, Haghighi P, et al. Abnormalities of articular cartilage in the knee: analysis of available MR techniques. Radiology 1993; 187: 4378.
  • 18
    Vahlensieck M, Dombrowski F, Leutner C, Wagner U, Reiser M. Magnetization transfer contrast (MTC) and MTC-subtraction: enhancement of cartilage lesions and intracartilaginous degeneration in vitro. Skeletal Radiol 1994; 23: 5359.
  • 19
    Bredella MA, Tirman PF, Peterfy CG, Zarlingo M, Feller JF, Bost FW, et al. Accuracy of T2-weighted fast spin-echo MR imaging with fat saturation in detecting cartilage defects in the knee: comparison with arthroscopy in 130 patients. Am J Roentgenol 1999; 172: 107380.
  • 20
    Kothari M, Guermazi A, von Ingersleben G, Miaux Y, Sieffert M, Block JE, et al. Fixed-flexion radiography of the knee provides reproducible joint space width measurements in osteoarthritis. Eur Radiol 2004; 14: 156873.
  • 21
    Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957; 16: 494502.
  • 22
    Bilinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997; 99: 153445.
  • 23
    Poole AR, Ionescu M, Fitzcharles MA, Billinghurst RC. The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases. J Immunol Methods 2004; 294: 14553.
  • 24
    Nelson F, Dahlberg L, Laverty S, Reiner A, Pidoux I, Ionescu M, et al. Evidence for altered synthesis of type II collagen in patients with osteoarthritis. J Clin Invest 1998; 102: 211525.
  • 25
    Rizkalla G, Reiner A, Bogoch E, Poole AR. Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis: evidence for molecular heterogeneity and extensive molecular changes in disease. J Clin Invest 1992; 90: 226877.
  • 26
    Christgau S, Garnero P, Fledelius C, Moniz C, Ensig M, Gineyts E, et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 2001; 29: 20915.
  • 27
    Garnero P, Ayral X, Rousseau JC, Christgau S, Sandell LJ, Dougados M, et al. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 2002; 46: 261324.
  • 28
    Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992; 7: 12518.
  • 29
    Garnero P, Shih W, Gineyts E, Karpf D, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994; 79: 1693700.
  • 30
    Verstappen SM, Poole AR, Ionescu M, King LE, Abrahamowicz M, Hofman DM, et al, and the Utrecht Rheumatoid Arthritis Cohort Study group (SRU). Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis. Arthritis Res Ther 2006; 8: R31.
  • 31
    Mazzuca SA, Poole AR, Brandt KD, Katz BP, Lane KA, Lobanok T. Associations between joint space narrowing and molecular markers of collagen and proteoglycan turnover in patients with knee osteoarthritis. J Rheumatol 2006; 33: 114751.
  • 32
    Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important participant relevant outcomes to antirheumatic drug therapy in participants with osteoarthritis of the hip or knee. J Rheumatol 1988; 15: 183340.
  • 33
    Stabler T, Fang F, Jordan J, Vilim V, Kraus VB. A comparison of methods for measuring cartilage oligomeric protein (COMP) in human subjects with knee OA [abstract]. Osteoarthritis Cartilage 2007; 15 Suppl C: C81.
  • 34
    Cahue S, Sharma L, Dunlop D, Ionescu M, Song J, Lobanok T, et al. The ratio of type II collagen breakdown to synthesis and its relationship with the progression of knee osteoarthritis. Osteoarthritis Cartilage 2007; 15: 81923.
  • 35
    Hunter DJ, Li Jiang, LaValley M, Bauer DC, Nevitt M, DeGroot J, et al. Cartilage markers and their association with cartilage loss on magnetic resonance imaging in knee osteoarthritis: the Boston Osteoarthritis Knee Study. Arthritis Res Ther 2007; 9: R108.
  • 36
    Hanna F, Ebeling PR, Wang Y, O'Sullivan R, Davis S, Wluka AE, et al. Factors influencing longitudinal change in knee cartilage volume measured from magnetic resonance imaging in healthy men. Ann Rheum Dis 2005; 64: 103842.
  • 37
    Bay-Jensen AC, Andersen TL, Charni-Ben Tabassi N, Kristensen PW, Kjaersgaard-Andersen P, Sandell L, et al. Biochemical markers of type II collagen breakdown and synthesis are positioned at specific sites in human osteoarthritic knee cartilage. Osteoarthritis Cartilage 2008; 16: 61523.
  • 38
    Dieppe P, Cushnaghan J, Young P, Kirwan J. Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy. Ann Rheum Dis 1993; 52: 55763.
  • 39
    Hart DJ, Spector TD. Kellgren & Lawrence grade 1 osteophytes in the knee: doubtful or definite? Osteoarthritis Cartilage 2003; 11: 14950.
  • 40
    Kong SY, Stabler TV, Criscione LG, Elliott AL, Jordan JM, Kraus VB. Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis. Arthritis Rheum 2006; 54: 2496504.